Review: NF-kB activation in canine cancer. Issue 5 (September 2022)

• Record Type: Journal Article
• Authors: Schlein, Lisa J.; Thamm, Douglas H.
• Is Part Of: Veterinary pathology. Volume 59:Issue 5(2022)
• Page Start: 724
• Page End: 732
• Publication Date: 2022-09
• Subjects: dog -- tumor -- neoplasia -- nuclear factor kappa B -- transcription factor; Veterinary pathology -- Periodicals; Pathology, Veterinary -- Periodicals; 636.089607
• DOI: 10.1177/03009858221092017
• Languages: English
• ISSNs: 0300-9858

Abstract

Spontaneous tumors in dogs share several environmental, epidemiologic, biologic, clinical and molecular features with a wide variety of human cancers, making this companion animal an attractive model. Nuclear factor kappa B (NF-kB) transcription factor overactivation is common in several human cancers, and there is evidence that similar signaling aberrations also occur in canine cancers including lymphoma, leukemia, hemangiosarcoma, mammary cancer, melanoma, glioma, and prostate cancer. This review provides an overview of NF-kB signaling biology, both in health and in cancer development. It also summarizes available evidence of aberrant NF-kB signaling in canine cancer, and reviews antineoplastic compounds that have been shown to inhibit NF-kB activity used in various types of canine cancers. Available data suggest that dogs may be an excellent model for human cancers that have overactivation of NF-kB.